Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia.
Eltrombopag
Erythropoiesis
Immunosuppressive therapy
Pure red cell aplasia
Refractory
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
13
09
2020
accepted:
03
02
2021
revised:
02
02
2021
pubmed:
22
2
2021
medline:
29
6
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Acquired pure red cell aplasia is a rare condition characterized by normocytic normochromic anemia with severe reticulocytopenia. In refractory acquired pure red cell aplasia, the low response rate of immunosuppressive therapy also constitutes a challenge. We herein report the case of a 58-year-old male with refractory acquired pure red cell aplasia that was successfully treated by eltrombopag at a dose of 75 mg/day. After application of eltrombopag, the patient achieved complete remission and tolerated the treatment very well, with only mild bilirubin elevation. These preliminary findings showed that eltrombopag may be effective and well tolerated in adult patients with refractory acquired pure red cell aplasia.
Identifiants
pubmed: 33611753
doi: 10.1007/s12185-021-03100-2
pii: 10.1007/s12185-021-03100-2
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
Receptors, Thrombopoietin
0
eltrombopag
S56D65XJ9G
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-128Subventions
Organisme : State Administration of Traditional Chinese Medicine Industry Specialty
ID : No.201407001-4
Organisme : National Public Health Grand Research Foundation
ID : No.201202017
Organisme : Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute
ID : No. JX10231801
Organisme : Project Funded by Jiangsu Provincial Special Program of Medical Science
ID : No. BL2014086
Références
Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504–9.
doi: 10.1182/blood-2016-05-717140
Xuemei Wu, Wang S, Xing-Yu Lu, Shen W, Qiao C, Yujie Wu, et al. Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. Int J Hematol. 2018;108:123–9.
doi: 10.1007/s12185-018-2446-y
Liu X, Xingyu Lu, Chen L, Xuemei Wu, Ruinan Lu, Wang S, et al. Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective. Ann Hematol. 2020;99(3):443–9.
doi: 10.1007/s00277-020-03926-6
Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol. 2017;8(5):159–74.
doi: 10.1177/2040620717693573
Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
doi: 10.1056/NEJMoa1200931
Gill H, Leung GM, Lopes D, Kwong YL. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 2017;176(6):991–4.
doi: 10.1111/bjh.14024
Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.
doi: 10.1182/blood-2013-10-534743
Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.
doi: 10.1016/j.scr.2012.05.001
Alvarado LJ, Huntsman HD, Cheng H, Townsley DM, Winkler T, Feng XM, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133(19):2043–55.
doi: 10.1182/blood-2018-11-884486
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212–20.
doi: 10.3324/haematol.2017.176339
Huang Y, Jiang X, Han B. Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report. Ther Adv Hematol. 2020;11:2040620720940144.
doi: 10.1177/2040620720940144
Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC Aplasia after Major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:1765–70.
doi: 10.1016/j.bbmt.2018.04.022
Dragani M, Andreani G, Familiari U, Marci V, Rege-Cambrin G. Pure red cell aplasia and amegakaryocytic thrombocytopenia in thymoma: the uncharted territory. Clin Case Rep. 2020;8:598–601.
doi: 10.1002/ccr3.2642
Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833–43.
doi: 10.2147/DDDT.S95715
Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018:450–6.
doi: 10.1182/asheducation-2018.1.450
Winkler T, Cooper JN, Townsley DM, Scheinberg P, Grasmeder S, Wu C, et al. Eltrombopag for refractory aplastic anemia: dosing regimens, long-term followup, clonal evolution and somatic mutation profiling. Blood. 2017;130(suppl 1):777.
doi: 10.1182/blood.V130.Suppl_1.777.777
Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2(4):454–61.
doi: 10.1182/bloodadvances.2017010660